Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs

Despite the success of imatinib in advanced gastrointestinal stromal tumor (GIST) patients, 50% of the patients experience resistance within two years of treatment underscoring the need to get better insight into the mechanisms conferring imatinib resistance. Here the microRNA and mRNA expression pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Amirnasr, Azadeh, Gits, Caroline M.M., van Kuijk, Patricia F., Smid, Marcel, Vriends, Anne L.M., Rutkowski, Piotr, Sciot, Raf, Schöffski, Patrick, Debiec-Rychter, Maria, Sleijfer, Stefan, Wiemer, Erik A. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627192/
https://www.ncbi.nlm.nih.gov/pubmed/31238586
http://dx.doi.org/10.3390/cancers11060882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627192/
https://www.ncbi.nlm.nih.gov/pubmed/31238586
http://dx.doi.org/10.3390/cancers11060882

Ejemplares similares